Navigation Links
FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology
Date:12/10/2009

the choice of the adult FAP patient population, selection of cohort size, the dosing regimen, and duration of treatment. The trial is designed to determine safety and tolerability of CEQ508, starting with a dose-escalation phase in which patients will be given one of four escalating concentrations of the drug, contingent upon safety monitoring. This initial part of the clinical trial is expected to take approximately six months. Next, following a safety review, the trial plan calls for a stable-dose phase in which additional patients will receive the highest safe dose. The FDA will permit daily dosing of 18 or more patients for 28 days. A key readout and secondary objective of the trial includes analysis of biomarker beta-catenin expression changes in the gastrointestinal tract of patients determined from biopsy samples obtained prior to taking the drug and at the end of the dosing period.

Cequent's Vice President of Drug Development, Alison Silva, commented, "I want to commend the reviewers at CBER who have been very responsive, providing critical feedback immediately following our submission and throughout the application process. They worked with us so that we could address their questions quickly and effectively to reach a successful conclusion by our action date."

With the FDA approval of Cequent's clinical-trial protocol now in hand, the company has begun working with the proposed clinical center to obtain the necessary institutional approvals. Cequent expects to begin the Phase I clinical trial during the first quarter of 2010 at the Fred Hutchinson Cancer Research Center in Seattle, Washington, part of the Fred Hutchinson/University of Washington Cancer Consortium. The Cancer Consortium maintains a registry of FAP patients and is also one of 40 National Cancer Institute-designated comprehensive cancer centers nationwide. Gideon Steinbach, M.D., Ph.D., is slated to be the principal investigator (PI) of the Cequent trial. Dr. Steinbach is
'/>"/>

SOURCE Cequent Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. SRI International Receives National Institutes of Health Grants to Develop Improved Tomographic Imaging Technology
2. The Epilepsy Research Foundation and Milken Family Foundation Announce Prestigious Translational Research Grants for Two Pioneering Epilepsy Therapies
3. U.S. Food And Drug Administration (FDA) Grants Traditional Approval for INTELENCE(R) (etravirine)
4. FDA Grants GeoVax Labs, Inc. Request For Pre-IND Meeting
5. Ganeden Biotech Announces Grants for Early Investigators to Research Probiotic GanedenBC30
6. Cephalon Announces that FDA Grants Priority Review of its Supplemental New Drug Application for NUVIGIL as a Treatment for Excessive Sleepiness Associated with Jet Lag Disorder
7. Octapharma Accepting Applications for Research Grants on Immunotherapy, Coagulation Disorders and Critical Care
8. Swissmedic Grants Debiopharm Marketing Authorisation for Moapar(R), a New Therapeutic Avenue for the Treatment of Sexual Deviations
9. Swissmedic Grants Debiopharm Marketing Authorisation for Moapar(R), a New Therapeutic Avenue for the Treatment of Sexual Deviations
10. Oasmia: FDA Grants Paclical(R) Orphan Drug Designation for Ovarian Cancer in the USA
11. Rendell Administration Announces Health Research Grants From Tobacco Settlement Funds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/1/2015)... The Middle Eastern MRI systems market is fast growing. MRI ... of its higher sensitivity and use of non-ionizing radiations. Open ... systems of MRI, open and closed. Open MRI systems have ... not enclose the patient in a tunnel. This prevents the ... one in every 6 patients suffers from claustrophobia hence the ...
(Date:6/1/2015)... LONDON , June 1,2015 The Middle Eastern ... important diagnostic tool is used in all domains of medicine ... like CT because of its better precision and is as ... is categories into 3 types based on equipment into Open ... system MRI has a growing market demand as it is ...
(Date:6/1/2015)... British Columbia and MENLO ... -- DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) ... on developing and commercializing proven cancer therapies in ... data from its Phase I/II clinical trial of  ... (GBM), the most common and deadly form of ...
Breaking Medicine Technology:Middle East Open System MRI Market - Growth, Trends And Forecasts (2014 - 2019) 2Middle East MRI Market - Growth, Trends And Forecasts (2014 - 2019) 2Middle East MRI Market - Growth, Trends And Forecasts (2014 - 2019) 3DelMar Pharmaceuticals Presents Updated Phase I/II Clinical Data on VAL-083 in Refractory Glioblastoma Multiforme (GBM) at ASCO 2DelMar Pharmaceuticals Presents Updated Phase I/II Clinical Data on VAL-083 in Refractory Glioblastoma Multiforme (GBM) at ASCO 3DelMar Pharmaceuticals Presents Updated Phase I/II Clinical Data on VAL-083 in Refractory Glioblastoma Multiforme (GBM) at ASCO 4DelMar Pharmaceuticals Presents Updated Phase I/II Clinical Data on VAL-083 in Refractory Glioblastoma Multiforme (GBM) at ASCO 5DelMar Pharmaceuticals Presents Updated Phase I/II Clinical Data on VAL-083 in Refractory Glioblastoma Multiforme (GBM) at ASCO 6DelMar Pharmaceuticals Presents Updated Phase I/II Clinical Data on VAL-083 in Refractory Glioblastoma Multiforme (GBM) at ASCO 7DelMar Pharmaceuticals Presents Updated Phase I/II Clinical Data on VAL-083 in Refractory Glioblastoma Multiforme (GBM) at ASCO 8
(Date:6/1/2015)... (PRWEB) June 01, 2015 More than 22 ... summer months when school is out and they lose access ... Month and America’s dairy farmers and milk companies are on ... need with The Great American Milk Drive. , In ... provided in the school cafeteria for the bulk of their ...
(Date:6/1/2015)... June 01, 2015 Northridge dentist ... now offering patients a promotion on Invisalign for a ... Invisalign treatment is reduced to $3,700. Patients can find ... complimentary consultation and discuss the extent of correction they ... cannot be combined with any other offer. , ...
(Date:6/1/2015)... Listen to Volvo’s Director of Connectivity Strategy, ... more granular data to create better customer oriented services. ... in Josep Celaya Gonzalez, CIO at MAPFRE, and Silvan ... automotive insurer, MAPFRE are well versed in capturing complex ... the driver. Award winning start-up ParkTAG offer an exciting ...
(Date:6/1/2015)... June 01, 2015 Hexagon Geospatial is ... is a new cloud-based subscription service that provides on-demand ... software. , Both ERDAS IMAGINE and ... Producer Online, which offers a subscription model for delivering ... need to be able to quickly and easily access ...
(Date:6/1/2015)... 2015 The session, entitled “Building the ... vice president of Elektrobit Automotive Americas, senior representatives ... it will be moderated by Andy Gryc of CX3 ... and complexity of in-vehicle software in connected vehicles and ... and how the wider ecosystem can fit into new ...
Breaking Medicine News(10 mins):Health News:Summer Nutrition Vital for Kids who Depend on Schools for Healthy Foods 2Health News:Northridge Dentists, Drs. Michel Elyson and Ramin Assili, are Now Offering a Limited Time Promotion on Invisalign 2Health News:Complimentary Webinar: Volvo, MAPFRE and Award Winning Start-Up discuss new Frontier of In-Car Services 2Health News:Hexagon Geospatial Launches Cloud-Based Producer Online Suite 2Health News:Hexagon Geospatial Launches Cloud-Based Producer Online Suite 3Health News:Elektrobit Automotive, Ford and Delphi to Tackle In-Vehicle Software at TU-Automotive Detroit 2015 2Health News:Elektrobit Automotive, Ford and Delphi to Tackle In-Vehicle Software at TU-Automotive Detroit 2015 3
... Sept. 3 Endo Pharmaceuticals (Nasdaq: ENDP ) ... the treatment of a distinct form of bladder cancer. VALSTAR ... Calmette-Guerin (BCG)-refractory carcinoma in situ (CIS) of the ... be associated with unacceptable medical risks. VALSTAR represents a ...
... owners to warning signs of PTSD, experts say , THURSDAY, ... was unaware that she was racing dangerously down the freeway ... nose nudge her elbow. , She immediately slowed down. , ... warning her that her anxiety levels were rising, a dangerous ...
... , Briefing is the first ... , WASHINGTON, Sept. 3 The following is ... , (Logo: http://www.newscom.com/cgi-bin/prnh/20090325/DC89081LOGO ) , ... Innovation will host a breakfast briefing on Capitol Hill titled "Education ...
... , EMERYVILLE, Calif., Sept. 3 Bionovo, Inc. (Nasdaq: ... from the phase 2 clinical trial of their lead drug candidate for ... Society for Gynecology (EGS) in Rome, Italy. , ... the safety and efficacy of two doses of Menerba versus placebo. The ...
... WASHINGTON, Sept. 3 The International Medical Interpreters ... building the organization,s international structure. The IMIA is proud ... Representative for Brazil. A medical interpreter trained in the ... now undergoing a Masters Program at Santa Catarina Federal ...
... , , ... and Drug Administration,s quest to dramatically reduce Salmonella-related food poisoning, ... country,s largest shell egg pasteurizer, opened a new state-of-the-art plant ... to eggs free from dangerous egg-related Salmonella-enteritidis. , , ...
Cached Medicine News:Health News:Endo Pharmaceuticals Introduces VALSTAR(TM) (Valrubicin) To Fill Unmet Need In Aggressive Form of Bladder Cancer 2Health News:Endo Pharmaceuticals Introduces VALSTAR(TM) (Valrubicin) To Fill Unmet Need In Aggressive Form of Bladder Cancer 3Health News:Endo Pharmaceuticals Introduces VALSTAR(TM) (Valrubicin) To Fill Unmet Need In Aggressive Form of Bladder Cancer 4Health News:Endo Pharmaceuticals Introduces VALSTAR(TM) (Valrubicin) To Fill Unmet Need In Aggressive Form of Bladder Cancer 5Health News:Service Dogs Help Traumatized Veterans Heal 2Health News:Service Dogs Help Traumatized Veterans Heal 3Health News:Council for American Medical Innovation to Host Capitol Hill Breakfast Briefing on Education and Immigration: The Building Blocks of Innovation 2Health News:Bionovo to Present Positive Results from Phase 2 Trial of Menerba for Vasomotor Symptoms to the International Community 2Health News:Bionovo to Present Positive Results from Phase 2 Trial of Menerba for Vasomotor Symptoms to the International Community 3Health News:Bionovo to Present Positive Results from Phase 2 Trial of Menerba for Vasomotor Symptoms to the International Community 4Health News:IMIA Interpreter Association Appoints Brazil Representative 2Health News:National Pasteurized Eggs Increases Access to Safe Pasteurized Shell Eggs With New Plant Opening During September's National Food Safety Education Month 2
Each handle is designed to fit a specific trephine size....
20 GA TITANIUM RETINAL FORCEPS...
... German Craftsmanship have produced ... in the world. Ocutek ... to you! Only holders ... certificate, which requires and ...
... German Craftsmanship have produced ... in the world. Ocutek ... to you! Only holders ... certificate, which requires and ...
Medicine Products: